{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T13:04:46Z","timestamp":1747487086091,"version":"3.37.3"},"reference-count":20,"publisher":"Consilium Medicum","issue":"2","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Aim. To define the frequency of adverse events and loss of the response in patients with ulcerative colitis (UC) and Crohns disease (CD), treated with original medicine infliximab (IFX) Remicaide and its biosimilars. Materials and methods. We included 154 patients with IBD: 78 UC patients (50.6%) \u0438 76 CD patients (49.4%), treated with original medicine IFX Remicade and its biosimilars. In our study we did not include patients, who previously underwent induction treatment with IFX and its biosimilar. Results. Among 78 UC patients, IFX was cancelled in 25 (32.0%) patients and they were switched to the other anti-TNF inhibitor or medicine with the another mechanism of action; in patients group, treated with biosimilar 16 (20.5%) and 9 (11.5%) patients, who were interchanged biosimilar and\/or original IFX. Among 76 CD patients IFX was cancelled in 20 (26.3%) patients: 11 (14.5%) patients in group, treated with similar trade name biosimilar, 8 (10.5%) patients, who were interchanged biosimilar and\/or original IFX and 1 patient (1,3%), receiving original IFX. We found no difference in the secondary loss of response and adverse events in patients with CD and UC, switched from original IFX to biosimilar (p=0.6257 and p=0.6635, correspondingly). The frequency of the secondary loss of response or adverse events in patients with UC and CD, switched from original IFX to IFX biosimilar, was similar (p0.05). Conclusion. Approximately 30% of IBD patients, receiving IFX biosimilar, will be switched to the other anti-TNF therapy or medicine with the another mechanism of action because of secondary loss of response or adverse events.<\/jats:p>","DOI":"10.26442\/00403660.2021.02.200624","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T10:17:28Z","timestamp":1617704248000},"page":"150-157","source":"Crossref","is-referenced-by-count":7,"title":["Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn\u2019s disease when switching from the original infliximab to its biosimilars"],"prefix":"10.26442","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7250-0977","authenticated-orcid":false,"given":"O. V.","family":"Knyazev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7937-2346","authenticated-orcid":false,"given":"M. Yu.","family":"Zvyaglova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-6205","authenticated-orcid":false,"given":"A. V.","family":"Kagramanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9508-7502","authenticated-orcid":false,"given":"I. A.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7519-2041","authenticated-orcid":false,"given":"E. A.","family":"Sabelnikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7891-2702","authenticated-orcid":false,"given":"A. A.","family":"Lishchinskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0855-5217","authenticated-orcid":false,"given":"D. S.","family":"Kulakov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9782-4860","authenticated-orcid":false,"given":"A. I.","family":"Parfenov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-017-0073-3"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.12.009"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.05.023"},{"key":"ref4","unstructured":"Kent D, Rickwood S, Di Biase S. Disruption and maturity: the next phase of biologics. 2017. Available at: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/nemea\/uk\/disruption_and_maturity_the_next_phase_of_biologics.pdf?_=1518214264988"},{"key":"ref5","unstructured":"Van den Hoven A. Biosimilar medicines clinical use: an experience-based EU perspective. 2017. Available at: https:\/\/www.medicinesforeurope.com\/docs\/20170713%20-%20Biosimilar%20Medicines%20Group,%20EU%20experience-AVH-US%20FDA%20Adcom.pdf"},{"key":"ref6","unstructured":"IQVIA. The impact of biosimilar competition in Europe. 2018. Available at: https:\/\/ec.europa.eu\/docsroom\/documents\/31642"},{"key":"ref7","unstructured":"QuintilesIMS. The impact of biosimilar competition in Europe. 2017. Available at: http:\/\/ec.europa.eu\/growth\/content\/impact-biosimilar-competition-price-volume-and-market-share-update-2017-0_en"},{"key":"ref8","unstructured":"EMA Guideline. Similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2015. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/documentJibrary\/Scientific_guideline\/2015\/01 \/WC500180219.pdf"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.26442\/00403660.2019.08.000331"},{"key":"ref10","unstructured":"\u0418\u0432\u0430\u0448\u043a\u0438\u043d \u0412.\u0422., \u0428\u0435\u043b\u044b\u0433\u0438\u043d \u042e.\u0410., \u0425\u0430\u043b\u0438\u0444 \u0418.\u041b. \u0438 \u0434\u0440. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439 \u0433\u0430\u0441\u0442\u0440\u043e\u044d\u043d\u0442\u0435\u0440\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u0430\u0441\u0441\u043e\u0446\u0438\u0430\u0446\u0438\u0438 \u0438 \u0410\u0441\u0441\u043e\u0446\u0438\u0430\u0446\u0438\u0438 \u043a\u043e\u043b\u043e\u043f\u0440\u043e\u043a\u0442\u043e\u043b\u043e\u0433\u043e\u0432 \u0420\u043e\u0441\u0441\u0438\u0438 \u043f\u043e \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0435 \u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u044e \u044f\u0437\u0432\u0435\u043d\u043d\u043e\u0433\u043e \u043a\u043e\u043b\u0438\u0442\u0430. \u041a\u043e\u043b\u043e\u043f\u0440\u043e\u043a\u0442\u043e\u043b\u043e\u0433\u0438\u044f. 2017;59(1):6-30 [Ivashkin VT, Shelygin YuA, Khalif IL, et al. Clinical recommendations of the Russian gastroenterological Association and the Association of coloproctologists of Russia on the diagnosis and treatment of ulcerative colitis. Coloproctology. 2017;59(1):6-30 (In Russ.)]."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"\u0418\u0432\u0430\u0448\u043a\u0438\u043d \u0412.\u0422., \u0428\u0435\u043b\u044b\u0433\u0438\u043d \u042e.\u0410., \u0425\u0430\u043b\u0438\u0444 \u0418.\u041b. \u0438 \u0434\u0440. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439 \u0433\u0430\u0441\u0442\u0440\u043e\u044d\u043d\u0442\u0435\u0440\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u0430\u0441\u0441\u043e\u0446\u0438\u0430\u0446\u0438\u0438 \u0438 \u0410\u0441\u0441\u043e\u0446\u0438\u0430\u0446\u0438\u0438 \u043a\u043e\u043b\u043e\u043f\u0440\u043e\u043a\u0442\u043e\u043b\u043e\u0433\u043e\u0432 \u0420\u043e\u0441\u0441\u0438\u0438 \u043f\u043e \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0435 \u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u044e \u0431\u043e\u043b\u0435\u0437\u043d\u0438 \u041a\u0440\u043e\u043d\u0430. \u041a\u043e\u043b\u043e\u043f\u0440\u043e\u043a\u0442\u043e\u043b\u043e\u0433\u0438\u044f. 2017;60(2):7-29 [Ivashkin VT, Shelygin YuA, Khalif IL, et al. Clinical recommendations of the Russian gastroenterological Association and the Association of coloproctologists of Russia for the diagnosis and treatment of Crohn\u2019s disease. Coloproctology. 2017;60(2):7-29 (In Russ.)].","DOI":"10.33878\/2073-7556-2018-0-3-7-23"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(80)92767-1"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1318.2008.01682.x"},{"key":"ref14","unstructured":"Mokhele NN, Tomson SR, Watermeyer GA. Predictors of emergency colectomy in patients admitted with acute severe ulcerative colitis. S Afr J Surg. 2017;55(3):20-6"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.08.012"},{"key":"ref16","unstructured":"Biosimilars in the EU. What I need to know about biosimilar medicines. Available at: https:\/\/www.ema.europa.eu\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf"},{"key":"ref17","unstructured":"Biosimilars action plan: balancing innovation and competition. 2018. Available at: https:\/\/www.fda.gov\/ucm\/groups\/fdagov-public\/@fdagov-drugs-gen\/documents\/document\/ucm613761.pdf"},{"key":"ref18","unstructured":"Emond B, Sadik K, Lafeuille M-H, et al. Switching Patterns Among Patients with Chronic Inflammatory Diseases Switching to an Infiximab Biosimilar or Remaining on Originator Infiximab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001113"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz203.614"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/64705\/47582","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/64705\/47582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T13:46:22Z","timestamp":1671803182000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/64705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,15]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2021.02.200624","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"type":"electronic","value":"2309-5342"},{"type":"print","value":"0040-3660"}],"subject":[],"published":{"date-parts":[[2021,2,15]]}}}